In ovarian cancer, important hormones using the extracellular signal-regulated kinase (ERK) pathway (e.g., gonadotropins and gonadotropin-releasing hormones) activate the KRAS-BRAF-MEK axis, and consecutively, ERK which can then activate transcription factors, including myc or elk-1. The gene discussed is KRAS; the disease is ovarian cancer.